Epclusa

Chemical Namesofosbuvir and velpatasvir
Dosage FormTablet (oral; sofosbuvir mg/velpatasvir mg: 400 mg/100 mg, 200 mg/50 mg)
Drug ClassAntivirals
SystemDigestive
CompanyGilead Sciences Inc.
Approval Year2016

Indication

  • For the treatment of adult and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection.
Last updated on 10/26/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Epclusa (sofosbuvir and velpatasvir) Prescribing Information 2020Gilead Sciences, Inc., Foster City, CA